Impact of gout on cardiovascular disease mortality: ameta-analysis.

Abstract

Several epidemiological studies have suggested that gout patients have ahigher risk of cardiovascular disease mortality than healthy people. In contrast, the association between gout and cardiovascular disease (CVD) mortality was not obvious in other studies. In the present study, we aimed to investigate the relative risk for CVD mortality in gout patients in comparison to healthy controls. Literature published before March 2023 was searched in Google Scholar, PubMed, and the Web of Science. We summarized the impact of gout on CVD mortality with ameta-analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) regarding the impact of gout on CVD mortality were summarized with STATA 12.0 software. Compared to individuals without gout, those with gout had higher mortality risks for CVD during follow-up, with arandom effects model showing arisk of 1.30 (95% CI 1.15 to 1.48, p < 0.001; p-value for CochranQ test < 0.001, I2 = 95.9%). Similarly, subjects with gout had amortality risk of 1.28 (95% CI 1.12 to 1.46, p < 0.001; p-value for CochranQ test = 0.050, I2 = 50.2%) for coronary heart disease (CHD) mortality during follow-up using the same statistical model. Furthermore, using afixed effects model, individuals with gout had amortality risk of 1.13 (95% CI 1.00 to 1.27, p = 0.049; p-value for CochranQ test = 0.494, I2 = 0.0%) for myocardial infarction (MI) mortality during follow-up. In conclusion, this meta-analysis provides evidence supporting amarkedly increased mortality risk from CVD and CHD as well as MI in patients with gout relative to reference subjects without gout.